The effect of anti-AFP-F(ab)’2 and adriamycin conjugate on transplantable tumors in mice

Abstract

Efficacy of the conjugate anti-AFF-F(ab)’2 with adriamycin, anti-AFP-F(ab)’2-adr, against transplantable tumors was studied in mice. The results showed that LD₅₀ of anti-AFP-F(ab)’2-adr in mice was 7.43 mg/kg and that anti-AFP-F(ab)’2-adr in a dose of 1/10 ™ 1/5 LD₅₀ could inhibit the growth of transplanted hepatocellular carcinoma. In addition, anti-AFP-F(ab)’2-adr with local application of AFP could markedly inhibit the growth of transplanted Ehrlich ascites cancer. From the above it is suggested that anti-AFP-F(ab)’2-adr can be used to treat hepatic carcinoma with satisfactory results.

Keywords

anti-AFP-F(ab)’2 / adriamycin / conjugate / transplanted tumors

References

[1] OrderSE, et al.. Use of isotopic immunoglobulin in therapy. Cancer Res, 1980, 40(9): 3001-7

[2] GarnettMC, et al.. Preparation and properties of a drugcarrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer, 1983, 31: 661-70

[3] ShihoSuruo. Relationship between AFP and histological patterns of hepatoma: localization of AFP in hepatoma cells using peroxidase antibody technique. Gann Monograph on Cancer Res, 1973, 8: 296-303

[4] NishiokaSeno. Immunofluorescence studies on AFP in hepatoma tissue. Gann Monograph on Cancer Res, 1973, 14: 205-9

[5] HurwirtzE, et al.. The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities. Cancer Res, 1975, 35(5): 1175-81